Sandu Pharmaceuticals Limited has announced its unaudited standalone financial results for the third quarter of FY26 ended 31st December 2025, demonstrating strong financial performance with significant profit growth. The Ayurvedic pharmaceutical company's results were approved by the board of directors during their meeting held on 6th February 2026.

Financial Performance Highlights

The company delivered impressive results for Q3FY26, with net profit reaching ₹97.51 lakhs compared to ₹55.55 lakhs in the corresponding quarter of the previous year. This represents substantial growth in profitability for the quarter. Revenue from operations stood at ₹1876.09 lakhs for Q3FY26, compared to ₹1837.29 lakhs in Q3FY25.

Nine-Month Performance

For the nine-month period ended 31st December 2025, Sandu Pharmaceuticals reported revenue from operations of ₹5308.10 lakhs and net profit of ₹172.27 lakhs. The company maintained consistent performance across the nine-month period with total income reaching ₹5316.04 lakhs.

Earnings Per Share and Capital Structure

The company reported basic and diluted earnings per share of ₹1.01 for Q3FY26, compared to ₹0.57 in Q3FY25. For the nine-month period, basic EPS stood at ₹1.78 compared to ₹1.27 in the previous year. The paid-up equity capital remained stable at ₹966.10 lakhs with a face value of ₹10 per share.

Comprehensive Income and Other Highlights

Total comprehensive income for Q3FY26 reached ₹114.47 lakhs, including other comprehensive income from fair value changes of investments amounting to ₹19.70 lakhs. For the nine-month period, total comprehensive income stood at ₹213.43 lakhs.

Corporate Governance and Compliance

The financial results were reviewed and recommended by the audit committee before being approved by the board of directors. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations. The company operates primarily in the Ayurvedic pharmaceutical medicines segment and maintains ISO 9001:2015 certification along with Good Manufacturing Practices (GMP) certification.

Sandu Pharmaceuticals Limited has announced that its Board of Directors will convene on February 06, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key corporate governance milestone as the company prepares to disclose its financial results for the third quarter of fiscal year 2026.

Board Meeting Details

The board meeting is scheduled with specific parameters that reflect the company's commitment to regulatory compliance and transparency.

Financial Results Review

The primary agenda item focuses on the approval of standalone unaudited financial results for the quarter ended December 31, 2025. This quarterly review will provide stakeholders with insights into the company's operational performance during the third quarter of fiscal year 2026. The board will also consider any additional matters that may arise with the chairman's permission.

Regulatory Compliance Measures

In adherence to SEBI regulations regarding insider trading prevention, Sandu Pharmaceuticals has implemented comprehensive compliance measures. The company has established a trading window closure that affects multiple stakeholder categories.

Corporate Communication

The formal communication was issued under reference number SPL/Corp.Sec/2025-26/24 dated January 24, 2026, and addressed to the Bombay Stock Exchange Limited. Company Secretary and Compliance Officer Pratika Mhambray signed the notification, ensuring proper documentation and regulatory adherence. The company operates under scrip code 524703 on the exchange and maintains its corporate office at the specified Mumbai location.

This scheduled board meeting demonstrates Sandu Pharmaceuticals' commitment to maintaining transparent communication with stakeholders and adhering to established corporate governance practices while ensuring compliance with securities market regulations.